Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2025)
Immatics' (IMTX) quarterly Liabilities and Shareholders Equity came in at $654.6 million in Q4 2025, down 12.01% year-on-year from $743.9 million in Q4 2024, and up 7.98% quarter-over-quarter from $606.2 million in Q3 2025.
Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends
Immatics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $654.6 million for Q4 2025.
- Liabilities and Shareholders Equity for Q4 2025 came in at $654.6 million, down 12.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.6 billion (down 6.68% YoY), and the FY2025 annual result was $635.3 million, down 14.59% from the prior year.
- Liabilities and Shareholders Equity came in at $654.6 million for Q4 2025 at Immatics, up from $606.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $743.9 million in Q4 2024 to a low of $199.8 million in Q4 2021.
- The 5-year median for Liabilities and Shareholders Equity is $461.4 million (2023), against an average of $484.2 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 119.32% in 2021, while the deepest fall reached 34.2% in 2021.
- Immatics' Liabilities and Shareholders Equity stood at $199.8 million in 2021, then soared by 108.26% to $416.1 million in 2022, then soared by 31.87% to $548.7 million in 2023, then jumped by 35.58% to $743.9 million in 2024, then fell by 12.01% to $654.6 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $654.6 million (Q4 2025), $606.2 million (Q3 2025), and $642.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 654.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 654.58 Mn |
| Sep 30, 2025 | 606.22 Mn |
| Jun 30, 2025 | 642.16 Mn |
| Mar 31, 2025 | 674.99 Mn |
| Dec 31, 2024 | 743.90 Mn |
| Sep 30, 2024 | 633.93 Mn |
| Jun 30, 2024 | 675.17 Mn |
| Mar 31, 2024 | 709.53 Mn |
| Dec 31, 2023 | 548.69 Mn |
| Sep 30, 2023 | 476.20 Mn |
| Jun 30, 2023 | 446.66 Mn |
| Mar 31, 2023 | 406.25 Mn |
| Dec 31, 2022 | 416.08 Mn |
| Sep 30, 2022 | 357.22 Mn |
| Jun 30, 2022 | 393.00 Mn |
| Mar 31, 2022 | 316.70 Mn |
| Dec 31, 2021 | 199.79 Mn |
| Sep 30, 2021 | 234.57 Mn |
| Jun 30, 2021 | 260.73 Mn |
| Mar 31, 2021 | 286.81 Mn |